Literature DB >> 28233446

Development of de novo psoriasis during nivolumab therapy for metastatic renal cell carcinoma: immunohistochemical analyses and clinical outcome.

Juan Ruiz-Bañobre1, Ihab Abdulkader2, Urbano Anido1, Luis León3, Rafael López-López1, Jorge García-González1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28233446     DOI： 10.1111/apm.12658

Source DB:  PubMed          Journal:  APMIS        ISSN： 0903-4641            Impact factor:   3.205


× No keyword cloud information.
  5 in total

1.  Ixekizumab for the treatment of erythrodermic psoriasis triggered by durvalumab-tremelimumab in a cancer patient.

Authors:  Arrieta Vinaixa Aranzazu; Víctor Morillas-Lahuerta; María Blanco De Tord; José-Manuel Carrascosa Carrillo
Journal:  Eur J Dermatol       Date:  2021-08-26       Impact factor: 2.805

2.  [Initially undetected de novo psoriasis triggered by nivolumab for metastatic base of the tongue carcinoma].

Authors:  S Troyanova-Slavkova; L Eickenscheidt; K Dumann; L Kowalzick
Journal:  Hautarzt       Date:  2018-08       Impact factor: 0.751

Review 3.  Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features.

Authors:  Samantha R Ellis; Aren T Vierra; Jillian W Millsop; Mario E Lacouture; Maija Kiuru
Journal:  J Am Acad Dermatol       Date:  2020-04-29       Impact factor: 11.527

4.  First-line Advanced Cutaneous Melanoma Treatments: Where Do We Stand?

Authors:  Louay S Abdulkarim; Richard J Motley
Journal:  JMIR Cancer       Date:  2021-12-15

5.  Psoriasis Vulgaris Exacerbation during Treatment with a PD-1 Checkpoint Inhibitor: Case Report and Literature Review.

Authors:  Marlies De Bock; Eva Hulstaert; Vibeke Kruse; Lieve Brochez
Journal:  Case Rep Dermatol       Date:  2018-08-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.